Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs Psoriasis: Opinion Leader Forum - Experts Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

Psoriasis: Opinion Leader Forum - Experts Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap

DateJan, 2001
Pages195
Price / format€10256 / Hard Copy

€10 000 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 The Genesis Group has prepared a report of Psoriasis Management and product technology to help you in establishing and monitoring your strategies for business development, product development, and marketing.

The report is based on interviews with researchers and clinicians, providers, academicians, pharmeceutical executives and MCOs.





The subject of this report is the management of psoriasis in the United States. More specifically, however, the subject has been approached primarily through in-depth interviews (a forum) with clinical and academic authorities, managed care medical and disease management executives, and pharmaceutical industry and therapeutic device manufacturer executives, so as to produce a close-in snapshot of the current opinions and attitudes of the thought leaders in the user segments of the pharmaceutical and drug-delivery marketplace for psoriasis products.





Table of contents:
 PSORIASIS: OPINION LEADER FORUM EXPERT’S VIEWS AND PERSPECTIVE ON DIAGNOSIS, TREATMENT, PRODUCT PERFORMANCE…AND CLOSING THE NEED GAP

TABLE OF CONTENTS

EXECUTIVE SUMMARY......................................................................................................................................... i
SECTION 1 INTRODUCTION................................................................................................................................ 1
1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1
1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 2
1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 3
SECTION 2 GENERAL ISSUES IN THE MANAGEMENT OF PSORIASIS.................................................... 5
2.1 FUNDAMENTALS OF THE CONDITION .............................................................................................. 5
2.2 PREVALENCE........................................................................................................................................ 10
2.3 IMPACT AND CHALLENGES OF PSORIASIS .................................................................................... 11
SECTION 3 CLINICAL MANAGEMENT OF PSORIASIS ............................................................................... 15
3.1 PHARMACEUTICAL STRATEGIES FOR MANAGING THE CONDITION...................................... 15
3.2 PATIENT CARE STRATEGIES.............................................................................................................. 27
SECTION 4 ISSUES IN CURRENT PHARMACEUTICAL APPROACHES TO THE MANAGEMENT OF
PSORIASIS.................................................................................................................................. 29
SECTION 5 PRODUCT DEVELOPMENT FOR THE MANAGEMENT OF PSORIASIS............................. 35
SECTION 6 THE PSORIASIS MARKET: DELIVERY SYSTEM ISSUES...................................................... 69
SECTION 7 NEEDS/GAPS ANALYSIS OF THE MANAGEMENT OF PSORIASIS ..................................... 77
7.1 NEEDS/GAPS IN THE CURRENT MANAGEMENT OF PSORIASIS ................................................ 77
7.2 ASPECTS OF THE CURRENT MANAGEMENT OF PSORIASIS NOT CONSIDERED
SUBSTANTIALLY PROBLEMATICAL................................................................................................ 86
ADDENDUM A NATIONAL PSORIASIS FOUNDATION: GUIDELINES AND OTHER INFORMATION
ON THE MANAGEMENT OF PSORIASIS............................................................................. 87
ADDENDUM B FUNCTIONALITY OF SKIN STRUCTURE.......................................................................... 121
B.1 EPIDERMIS, DERMIS, AND SUBCUTANEOUS LAYER................................................................. 121
B.2 SKIN AND THE IMMUNE SYSTEM................................................................................................... 122
B.3 AGING AND THE SKIN ....................................................................................................................... 123
ADDENDUM C REVIEW OF SELECTED PHARMACEUTICAL MANUFACTURERS THAT ARE
STAKEHOLDERS IN PSORIASIS AND OTHER DERMATOLOGICAL CONDITIONS
..................................................................................................................................................... 127
C.1 ABBOTT LABORATORIES ................................................................................................................. 128
C.2 ALLERGAN.......................................................................................................................................... 129
C.3 AMERICAN HOME PRODUCTS......................................................................................................... 132
C.4 AVENTIS............................................................................................................................................... 134
C.5 BOEHRINGER INGELHEIM................................................................................................................ 135
C.6 BRISTOL-MYERS SQUIBB ................................................................................................................. 136
C.7 GENZYME............................................................................................................................................ 139
C.8 GLAXOSMITHKLINE .......................................................................................................................... 141
C.9 IMMUNEX............................................................................................................................................ 143
C.10 JOHNSON & JOHNSON ....................................................................................................................... 145
C.11 MERCK & CO....................................................................................................................................... 147
C.12 MERCK GROUP................................................................................................................................... 149
C.13 NOVARTIS ........................................................................................................................................... 150
C.14 PFIZER .................................................................................................................................................. 153
C.15 PHARMACIA........................................................................................................................................ 155
C.16 ROCHE.................................................................................................................................................. 156
C.17 SCHERING AG..................................................................................................................................... 159
C.18 SCHERING-PLOUGH ........................................................................................................................... 160
ADDENDUM D PSORIASIS BACKGROUND - THE DISEASE, PRODUCT TECHNOLOGIES AND KEY
STAKEHOLDERS.................................................................................................................... 163
D.1 INTRODUCTION AND PHARMACOLOGIC MANAGEMENT OF PSORIASIS............................. 163
D.2 PRODUCT TECHNOLOGY EVALUATION AND FORECAST FOR PSORIASIS........................... 163
D.3 COMPETITIVE DEVELOPMENTS AND IMPLICATIONS FOR PSORIASIS ................................. 166
ADDENDUM E SELECTED RECENT EVENTS IN THE MANAGEMENT OF PSORIASIS .................... 169
E.1 MAJOR ADVANCES IN PSORIASIS THERAPY WERE PRESENTED AT THE JUNE 2001 SAN
FRANCISCO, CA, PSORIASIS ORGANIZATION MEETINGS......................................................... 170
E.2 TRIALS FOR PSORIASIS TREATMENT: AMEVIVE (ALEFACEPT) ............................................. 171
E.3 EVALUATION OF THE SAFETY OF AMEVIVE (ALEFACEPT) .................................................... 172
E.4 BIOGEN COMPLETES PHASE III TRIALS OF AMEVIVE (ALEFACEPT) AND WILL FILE
APPLICATIONS FOR WORLDWIDE MARKETING APPROVALS................................................. 173
E.5 XANELIM (EFALIZUMAB) FINDINGS PRESENTED FROM THE FIRST OF TWO PHASE III
CLINICAL TRIALS ............................................................................................................................... 174
E.6 PRELIMINARY LONG-TERM DATA HAVE BEEN ASSEMBLED ON THE INVESTIGATIONAL
BIOLOGIC THERAPY REMICADE (INFLIXIMAB) FOR PSORIASIS............................................ 176
E.7 ISOTECHNIKA, INC., RECEIVED US FDA APPROVAL TO BEGIN PHASE II CLINICAL TRIALS
FOR ISA(TX) 247 ................................................................................................................................. 177
E.8 RESULTS OF STUDIES ON VASOGEN’S IMMUNE MODULATION THERAPY WERE
PRESENTED AT THE 62ND ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE
DERMATOLOGY................................................................................................................................. 178
E.9 VASOGEN AND CANVAC ANNOUNCED RESEARCH COLLABORATION................................ 179
E.10 ISIS PHARMACEUTICALS INITIATED A PHASE II CLINICAL TRIAL OF TOPICAL ISIS 104838,
A TNF-ALPHA INHIBITOR, FOR PSORIASIS................................................................................... 180
E.11 PHASE II CLINICAL TRIAL OF ISIS 2302 FOR TREATING PSORIATIC PLAQUES ................... 181
E.12 MEDIMMUNE EXPANDS PHASE II PSORIASIS PROGRAM FOR MEDI-507 (SIPLIZUMAB)... 182
E.13 INITIAL CLINICAL RESULTS FOR MEDI-507 (SIPLIZUMAB) AS PSORIASIS
TREATMENT ....................................................................................................................................... 183
E.14 ALEXION ANNOUNCED COMPLETION OF PHASE I PSORIASIS PILOT SAFETY STUDY FOR
5G1.1 ..................................................................................................................................................... 185
E.15 PROTEIN DESIGN LABS ANNOUNCED DEVELOPMENT OF SMART ANTI-IL- 12
ANTIBODY........................................................................................................................................... 185
E.16 PROTEIN DESIGN LABS PRESENTED THREE HUMANIZED ANTIBODIES IN CLINICAL
DEVELOPMENT FOR PSORIASIS AT THE 2001 SAN FRANCISCO, CA, INTERNATIONAL
PSORIASIS SYMPOSIUM.................................................................................................................... 186
E.17 PHOTOMEDEX FILED WITH THE US FDA TO COMMERCIALLY MARKET XTRAC LASER
SYSTEM FOR TREATMENT OF ATOPIC DERMATITIS................................................................. 188
E.18 PHOTOMEDEX REPORTED ON THE STATUS OF COVERAGE AND REIMBURSEMENT FOR
THE XTRAC LASER TREATMENT FOR MILD-TO-MODERATE PSORIASIS ............................. 188
E.19 PHOTOGEN COMMENCED PHASE I STUDY OF PH-10 FOR PSORIASIS ................................... 189
E.20 LECTEC CORPORATION INTRODUCED ITS OVER-THE-COUNTER THERAPATCH FOR
PSORIASIS AND SEBORRHEIC DERMATITIS ................................................................................ 189
E.21 PSORIASIS SUSCEPTIBILITY — NIH DOCUMENT NUMBER 177900......................................... 190

LIST OF TABLES

Table 1 Programs in Development - Psoriasis........................................................................................... 164
Table 2 Historic Sales by Technology - Psoriasis ..................................................................................... 166
Table 3 Significant Products Marketed 1997-2000 - Psoriasis.................................................................. 167
Table 4 Historic Sales by Firm - Psoriasis................................................................................................. 167




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com